PortalPublikationenDrugs targeting integrins for cancer therapy

Drugs targeting integrins for cancer therapy

Standard

Drugs targeting integrins for cancer therapy. / Binder, Mascha; Trepel, Martin.

in: EXPERT OPIN DRUG DIS, Jahrgang 4, Nr. 3, 03.2009, S. 229-41.

Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung

Harvard

Binder, M & Trepel, M 2009, 'Drugs targeting integrins for cancer therapy', EXPERT OPIN DRUG DIS, Jg. 4, Nr. 3, S. 229-41. https://doi.org/10.1517/17460440902751581

APA

Binder, M., & Trepel, M. (2009). Drugs targeting integrins for cancer therapy. EXPERT OPIN DRUG DIS, 4(3), 229-41. https://doi.org/10.1517/17460440902751581

Vancouver

Binder M, Trepel M. Drugs targeting integrins for cancer therapy. EXPERT OPIN DRUG DIS. 2009 Mär;4(3):229-41. https://doi.org/10.1517/17460440902751581

Bibtex

@article{3570315efde7496088b4e8f28011c419,
title = "Drugs targeting integrins for cancer therapy",
abstract = "BACKGROUND: Integrins are cell adhesion receptors involved in development, angiogenesis, blood clotting, inflammation and cancer. Abnormal integrin expression is a hallmark of cancer and angiogenic endothelial cells. Integrin-targeted therapy is, therefore, considered a promising novel treatment approach in oncology.OBJECTIVE: We describe the biological background making integrins an attractive therapeutic target as well as the effects of integrin-targeted therapies in preclinical and clinical settings.METHODS: A literature search in integrin-targeted therapy was conducted, focusing on αvβ3, αvβ5, α5β1 and α4β1 integrin ligands as well as in vivo models and clinical trials.RESULTS/CONCLUSION: Blocking certain integrins can inhibit tumor growth and integrin ligands can be used to target cytotoxic agents to cancer tissue. Clinical trials using integrin inhibitors have yielded variable results and continuing studies evaluate their role as monotherapy or in combination with chemo- or radiotherapy.",
keywords = "Journal Article",
author = "Mascha Binder and Martin Trepel",
year = "2009",
month = mar,
doi = "10.1517/17460440902751581",
language = "English",
volume = "4",
pages = "229--41",
journal = "EXPERT OPIN DRUG DIS",
issn = "1746-0441",
publisher = "informa healthcare",
number = "3",

}

RIS

TY - JOUR

T1 - Drugs targeting integrins for cancer therapy

AU - Binder, Mascha

AU - Trepel, Martin

PY - 2009/3

Y1 - 2009/3

N2 - BACKGROUND: Integrins are cell adhesion receptors involved in development, angiogenesis, blood clotting, inflammation and cancer. Abnormal integrin expression is a hallmark of cancer and angiogenic endothelial cells. Integrin-targeted therapy is, therefore, considered a promising novel treatment approach in oncology.OBJECTIVE: We describe the biological background making integrins an attractive therapeutic target as well as the effects of integrin-targeted therapies in preclinical and clinical settings.METHODS: A literature search in integrin-targeted therapy was conducted, focusing on αvβ3, αvβ5, α5β1 and α4β1 integrin ligands as well as in vivo models and clinical trials.RESULTS/CONCLUSION: Blocking certain integrins can inhibit tumor growth and integrin ligands can be used to target cytotoxic agents to cancer tissue. Clinical trials using integrin inhibitors have yielded variable results and continuing studies evaluate their role as monotherapy or in combination with chemo- or radiotherapy.

AB - BACKGROUND: Integrins are cell adhesion receptors involved in development, angiogenesis, blood clotting, inflammation and cancer. Abnormal integrin expression is a hallmark of cancer and angiogenic endothelial cells. Integrin-targeted therapy is, therefore, considered a promising novel treatment approach in oncology.OBJECTIVE: We describe the biological background making integrins an attractive therapeutic target as well as the effects of integrin-targeted therapies in preclinical and clinical settings.METHODS: A literature search in integrin-targeted therapy was conducted, focusing on αvβ3, αvβ5, α5β1 and α4β1 integrin ligands as well as in vivo models and clinical trials.RESULTS/CONCLUSION: Blocking certain integrins can inhibit tumor growth and integrin ligands can be used to target cytotoxic agents to cancer tissue. Clinical trials using integrin inhibitors have yielded variable results and continuing studies evaluate their role as monotherapy or in combination with chemo- or radiotherapy.

KW - Journal Article

U2 - 10.1517/17460440902751581

DO - 10.1517/17460440902751581

M3 - SCORING: Journal article

C2 - 23489123

VL - 4

SP - 229

EP - 241

JO - EXPERT OPIN DRUG DIS

JF - EXPERT OPIN DRUG DIS

SN - 1746-0441

IS - 3

ER -